Analiza fuzij z metodo NGS v sarkomih in drugih tumorjih s translokacijami (FusioPlex Sarcoma ali FusionPlex Sarcoma v2)

  • fuzije (z znanimi in neznanimi partnerji):
    ALK, BCOR, BRAF, CAMTA1, CCNB3, CIC, CSF1, EGFR, EPC1, ERG, ESR1, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FOS, FOSB, FOXO1, FUS, GLI1, HMGA2, JAZF1, MBTD1, MDM2, MEAF6, MET, MGEA5, MKL2, NCOA1, NCOA2, NCOA3, NR4A3, NTRK1, NTRK2, NTRK3, NUTM1, PAX3, PDGFB, PDGFRA, PHF1, PLAG1, PRKCA, PRKCB, PRKCD, RAF1, RET, ROS1, SS18, STAT6, TAF15, TCF12, TFE3, TFG, USP6, VGLL2, YAP1 in YWHAE
  • geni z visoko frekvenco klinično pomembnih somatskih mutacij (»hotspots«):
    ALK, BRAF, CTNNB1, EGFR, ETV6, FGFR1, FGFR2, FGFR3, MYOD1, NTRK1, NTRK2, NTRK3, PDGFRA, RET in ROS1